Early Phase I Study of a (99m)Tc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced non–small cell lung cancer. Treatment stratification depends on immunohistochemical PD-L1 measurement of biopsy material, an invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Yan, Chand, Gitasha, Liu, Changchun, Cook, Gary J.R., O’Doherty, Jim, Zhao, Lingzhou, Wong, Nicholas C.L., Meszaros, Levente K., Ting, Hong Hoi, Zhao, Jinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735283/
https://www.ncbi.nlm.nih.gov/pubmed/30796165
http://dx.doi.org/10.2967/jnumed.118.224170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735283/
https://www.ncbi.nlm.nih.gov/pubmed/30796165
http://dx.doi.org/10.2967/jnumed.118.224170

Ejemplares similares